Tess Flannery1, Jonathan M Davis2, Adam J Czynski3, Lynne M Dansereau1, Erica L Oliveira1, Samantha A Camardo1, Barry M Lester4. 1. Brown Center for the Study of Children at Risk and Women and Infants Hospital, Providence, RI. 2. Department of Pediatrics, The Floating Hospital for Children at Tufts Medical Center, Boston, MA; Tufts Clinical and Translational Science Institute, Boston, MA; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA. 3. Department of Pediatrics, Warren Alpert Medical School of Brown University and Women and Infants Hospital, Providence, RI. 4. Brown Center for the Study of Children at Risk and Women and Infants Hospital, Providence, RI; Department of Pediatrics, Warren Alpert Medical School of Brown University and Women and Infants Hospital, Providence, RI; Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI. Electronic address: Barry_Lester@Brown.edu.
Abstract
OBJECTIVE: To develop an index to determine which opioid-exposed neonates have the most severe neonatal abstinence syndrome (NAS). STUDY DESIGN: Full-term neonates with NAS (n = 116) from mothers maintained on methadone or buprenorphine were enrolled from 8 sites into a randomized clinical trial of morphine vs methadone. Ninety-nine (85%) were evaluated at hospital discharge using the NICU Network Neurobehavioral Scale (NNNS). At 18 months, 83 of 99 (83.8%) were evaluated with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), and 77 of 99 (77.7%) were evaluated with the Child Behavior Checklist (CBCL). RESULTS: Cluster analysis was used to define high (n = 21) and low (n = 77) NAS severity. Compared with infants in the low NAS severity cluster, infants in the high NAS severity cluster had a longer length of stay (P < .001), longer length of stay due to NAS (P < .001), longer duration of treatment due to NAS (P < .001), and higher total dose of the study drug (P < .001) and were more likely to have received phenobarbital (P < .001), to have been treated with morphine (P = .020), and to have an atypical NNNS profile (P = .005). The 2 groups did not differ in terms of maximum Finnegan score. At 18 months, in unadjusted analyses, compared with the high-severity cluster, the low-severity cluster had higher scores on the Bayley-III Cognitive (P = .013), Language (P < .001), and Motor (P = .041) composites and less total behavior problems on the CBCL (P = .028). In adjusted analyses, the difference in the Bayley-III Language composite remained (P = .013). CONCLUSIONS: Presumptive measures of NAS severity can be aggregated to develop an index that predicts developmental outcomes at age 18 months.
RCT Entities:
OBJECTIVE: To develop an index to determine which opioid-exposed neonates have the most severe neonatal abstinence syndrome (NAS). STUDY DESIGN: Full-term neonates with NAS (n = 116) from mothers maintained on methadone or buprenorphine were enrolled from 8 sites into a randomized clinical trial of morphine vs methadone. Ninety-nine (85%) were evaluated at hospital discharge using the NICU Network Neurobehavioral Scale (NNNS). At 18 months, 83 of 99 (83.8%) were evaluated with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), and 77 of 99 (77.7%) were evaluated with the Child Behavior Checklist (CBCL). RESULTS: Cluster analysis was used to define high (n = 21) and low (n = 77) NAS severity. Compared with infants in the low NAS severity cluster, infants in the high NAS severity cluster had a longer length of stay (P < .001), longer length of stay due to NAS (P < .001), longer duration of treatment due to NAS (P < .001), and higher total dose of the study drug (P < .001) and were more likely to have received phenobarbital (P < .001), to have been treated with morphine (P = .020), and to have an atypical NNNS profile (P = .005). The 2 groups did not differ in terms of maximum Finnegan score. At 18 months, in unadjusted analyses, compared with the high-severity cluster, the low-severity cluster had higher scores on the Bayley-III Cognitive (P = .013), Language (P < .001), and Motor (P = .041) composites and less total behavior problems on the CBCL (P = .028). In adjusted analyses, the difference in the Bayley-III Language composite remained (P = .013). CONCLUSIONS: Presumptive measures of NAS severity can be aggregated to develop an index that predicts developmental outcomes at age 18 months.
Authors: Ludmila N Bakhireva; Bradley D Holbrook; Shikhar Shrestha; Yuridia Leyva; Malia Ashley; Sandra Cano; Jean Lowe; Julia M Stephen; Lawrence Leeman Journal: Early Hum Dev Date: 2018-12-13 Impact factor: 2.079
Authors: Barry M Lester; Edward Z Tronick; Linda LaGasse; Ronald Seifer; Charles R Bauer; Seetha Shankaran; Henrietta S Bada; Linda L Wright; Vincent L Smeriglio; Jing Lu; Loretta P Finnegan; Penelope L Maza Journal: Pediatrics Date: 2002-12 Impact factor: 7.124
Authors: Alison Volpe Holmes; Emily C Atwood; Bonny Whalen; Johanna Beliveau; J Dean Jarvis; John C Matulis; Shawn L Ralston Journal: Pediatrics Date: 2016-06 Impact factor: 7.124
Authors: Elizabeth Allocco; Marjorie Melker; Florencia Rojas-Miguez; Caitlin Bradley; Kristen A Hahn; Elisha M Wachman Journal: Adv Neonatal Care Date: 2016-10 Impact factor: 1.968
Authors: Sophie van der Sluis; Tinca J C Polderman; Michael C Neale; Frank C Verhulst; Danielle Posthuma; Gwen C Dieleman Journal: Int J Methods Psychiatr Res Date: 2016-01-22 Impact factor: 4.035
Authors: Mara G Coyle; Amy L Salisbury; Barry M Lester; Hendrée E Jones; Hai Lin; Klaudia Graf-Rohrmeister; Gabriele Fischer Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Marie Camerota; Jonathan M Davis; Lynne M Dansereau; Erica L Oliveira; James F Padbury; Barry M Lester Journal: J Pediatr Date: 2021-12-28 Impact factor: 4.406
Authors: Elisabeth C McGowan; Julie A Hofheimer; T Michael O'Shea; Howard Kilbride; Brian S Carter; Jennifer Check; Jennifer Helderman; Charles R Neal; Steve Pastyrnak; Lynne M Smith; Marie Camerota; Lynne M Dansereau; Sheri A Della Grotta; Barry M Lester Journal: JAMA Netw Open Date: 2022-07-01